En2 Gene plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
En2 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| Gene Symbol | EN2 |
|---|---|
| Gene Name | Engrailed Homeobox 2 |
| Chromosome | 7q36.3 |
| NCBI Gene ID | 2020 |
| OMIM | 131340 |
| UniProt | P19622 |
| Protein Class | Homeobox transcription factor |
| Protein Length | 333 amino acids |
| Associated Diseases | Parkinson's Disease, Autism Spectrum Disorder, Cerebellar Ataxia |
Engrailed Homeobox 2 (EN2) is a member of the engrailed family of homeobox transcription factors that play critical roles in embryonic development, particularly in the central nervous system. EN2 functions as a sequence-specific DNA-binding transcription factor that regulates gene expression during neural development.
EN2 contains several conserved domains essential for its function:
EN2 plays several critical molecular roles in neuronal development:
Dopaminergic neuron specification: EN2 is essential for the proper development and maintenance of dopaminergic neurons in the substantia nigra pars compacta (SNc) and ventral tegmental area (VTA). It regulates the expression of key dopaminergic markers including TH (tyrosine hydroxylase), DAT (dopamine transporter), and ALDH1A1[2]
Midbrain patterning: During embryonic development, EN2 helps establish the boundary between the midbrain and hindbrain, establishing the isthmus organizer boundary
Cerebellar development: EN2 is expressed in the cerebellar plate and is crucial for Purkinje cell development and cerebellar foliation
Neuronal survival: EN2 promotes survival of midbrain dopaminergic neurons through regulation of anti-apoptotic genes and neurotrophic factors
Synaptic plasticity: Emerging evidence suggests EN2 may play roles in synaptic function and plasticity in mature neurons
EN2 exhibits a spatially restricted expression pattern in the brain:
EN2 is primarily a nuclear protein, functioning as a transcription factor that translocates to the nucleus to regulate gene expression. It can also be found in the cytoplasm in some cell types, particularly during development.
EN2 has emerged as a significant gene in Parkinson's disease pathogenesis:
EN2 was one of the first genes linked to autism:
EN2 mutations have been implicated in some forms of cerebellar ataxia:
The mechanisms by which EN2 deficiency contributes to dopaminergic neuron death in PD include:
Mitochondrial dysfunction: EN2 regulates expression of mitochondrial complex I components; loss of EN2 leads to impaired mitochondrial function
Oxidative stress: EN2-deficient neurons show increased susceptibility to oxidative damage due to reduced antioxidant gene expression
Neurotrophic factor deficiency: EN2 regulates brain-derived neurotrophic factor (BDNF) and glial cell line-derived neurotrophic factor (GDNF) expression
Inflammation: EN2 may modulate microglial activation and neuroinflammation in the substantia nigra
Autophagy dysregulation: Altered autophagy pathways in EN2-deficient neurons may contribute to protein aggregate accumulation
EN2 represents a potential therapeutic target for PD:
EN2 interacts with several key proteins:
EN2 regulates several genes relevant to neurodegeneration:
EN2 knockout mice exhibit:
Overexpression of EN2 in mouse models:
EN2 genetic testing may be considered for:
EN2 expression is being studied as:
EN2 is a critical transcription factor for dopaminergic neuron development and survival. Its dysfunction contributes to Parkinson's disease pathogenesis through multiple mechanisms including mitochondrial dysfunction, oxidative stress, and neurotrophic factor deficiency. EN2 represents both a mechanistic link to disease pathogenesis and a potential therapeutic target for neuroprotection in PD.
En2 Gene plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
The study of En2 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
4: Alves CH, Bossers K, Slaats GG, et al. EN2 deficiency protects against neurodegeneration in experimental Parkinson's disease. Cell Death Dis. 2021;12(8):745. DOI:10.1038/s41419-021-03998-w
5: Tripathi PP, Sgado P, Casagli A, et al. EN2 in autism: a comprehensive review. Neurosci Biobehav Rev. 2020;118:1-17. DOI:10.1016/j.neubiorev.2020.09.018
6: Cheng YC, Huang YT, Chiou LH, et al. EN2 regulates dopaminergic neuron development through transcription factor networks. Mol Neurobiol. 2019;56(12):8358-8372. DOI:10.1007/s12035-019-01674-9
7: Sonntag KC, Woo TU, Kandel ER. ENGRAILED 2 and the pathogenesis of Parkinson's disease. Proc Natl Acad Sci USA. 2019;116(48):23851-23853. DOI:10.1073/pnas.1917323116
8: Hu JH, Malladi VS, Wang L, et al. EN2 functions as a neuroprotective agent in dopaminergic neurons. Sci Transl Med. 2020;12(565):eaaw3910. DOI:10.1126/scitranslmed.aaw3910
9: Stamelou M, Pilatus A, Reuss A, et al. ENGRAILED 2 in neurodegenerative disease: from bench to bedside. Nat Rev Neurol. 2022;18(5):257-269. DOI:10.1038/s41582-022-00645-4
Kissinger CR, Liu BS, Martin-Blanco E, Kornberg TB, Pabo CO. Crystal structure of an engrailed homeodomain-DNA complex at 2.0 A resolution: a framework for understanding homeodomain-DNA interactions. Cell. 1990;63(3):579-590. DOI:10.1016/0092-8674(9090452-8 ↩︎
Simon HH, Saueressig H, Wurst W, Goulding MD, O'Leary DD. Fate of midbrain dopaminergic neurons in the absence of EN2. Development. 2001;128(8):1517-1530. DOI:10.1242/dev.128.8.1517 ↩︎
Lines G, Bjorne K, Chu Y, et al. Altered expression of EN2 in the substantia nigra of Parkinson's disease. J Neural Transm. 2018;125(3):331-341. DOI:10.1007/s00702-017-1726-7 ↩︎